Introduction Valuing pharmaceutical companies is a complex yet crucial task for investors, analysts, and stakeholders. The unique nature of the […]
Valuation of Pharma Companies: 5 Key Considerations Read Post »
Amid public outcry over rising costs of brand-name drugs, the prices of generic medicines have been falling, raising fears about
This paper was originally published by Melek Simsek, Berrie Meijer, Adriaan A.van Bodegraven, Nanne K.H. de Boer, and Chris J.J.
When referring to “big data” in the context of the drug industry, one should essentially think of a collection of
Generic drugs perform better financially if they get to market first. The advantage is amplified if they get there more than one month ahead of competitors.
Loss of exclusivity doesn’t mean the end of the income stream for branded drugs. Here’s how drug companies can mitigate the effects of drug patent expiration.
6 Ways to Maximize Product Value as Loss of Exclusivity Approaches Read Post »
Considering switching to DrugPatentWatch? See why others have come to us. DrugPatentWatch Alternatives
This paper was originally published by Ingrid Freije, Stéphane Lamouche, and Mario Tanguay in Therapeutic Innovation & Regulatory Science under
Generic drug makers must tailor European market entry strategies to each country. Moreover, they must address the sequence in which they want to enter markets.
Generic Drug Market Entry in Europe: Why a Tailored Approach Is Best Read Post »
Get fresh news and insights, drug patent expirations & more…
